FDA Approves New Treatment for Certain Neuroendocrine Tumors

| February 8, 2018 | 0 Comments
FDA Approves New Treatment for Certain Neuroendocrine Tumors

People with cancerous neuroendocrine tumors (NETs) that affect the digestive tract now have a new treatment option. On January 29, FDA approved the targeted treatment lutetium Lu 177 dotatate (Lutathera®) for adult patients with advanced NETs that affect the pancreas or gastrointestinal tract.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply